Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk ASLTS:0QIU -4.86%76 FCF Margin % is 54.02% as of Jun. 2026, which is 85% above its 10-year median of 29.13. GuruFocus rates LTS:0QIU with a GF Score™ of 76/100 and a GF Value™ of kr698.10 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 962 Drug Manufacturers companies, Novo Nordisk AS ranks better than 80.25% on this metric.
The historical data trend for Novo Nordisk AS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QIU vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (LTS:0QIU) has a FCF Margin % of 54.02% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novo Nordisk AS and its competitors. This is 85% above median its historical median of 29.13. Over the past decade, Novo Nordisk AS's FCF Margin % has ranged from 9.38 to 36.24. According to the industry distribution chart, Novo Nordisk AS ranks #190 out of 962 companies in the Drug Manufacturers industry, placing it in the top 19.8%.
Is Novo Nordisk AS's FCF Margin % too high?
Novo Nordisk AS's current FCF Margin % of 54.02% is 85% above median its 10-year median of 29.13. Over the past 10 years, this metric has ranged from a low of 9.38 to a high of 36.24. The Drug Manufacturers industry median FCF Margin % is 2.51. Novo Nordisk AS's value of 54.02% is 2052.2% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #190 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #190 out of 962 companies for FCF Margin %. This places Novo Nordisk AS in the top 20% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Novo Nordisk AS's value of 54.02% is 2052.2% above this benchmark. Historically, Novo Nordisk AS's own FCF Margin % has ranged from 9.38 to 36.24 over the past decade. While the company's 10-year median is 29.13 vs. the industry median of 2.51, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current FCF Margin % of 54.02% is 2052.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current FCF Margin % is 54.02%, which is 85% above median its own 10-year median of 29.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (LTS:0QIU) is currently considered Significantly Undervalued. The stock's GF Value™ is kr698.10, compared to a current price of kr291.00 — trading 58.3% below its estimated fair value. The current FCF Margin % is 54.02%, which is 85% above median its 10-year median of 29.13 and 2052.2% above the Drug Manufacturers industry median of 2.51. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Novo Nordisk AS (LTS:0QIU), the current FCF Margin % is 54.02% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (LTS:0QIU) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of kr291.00 is trading 58.3% below its estimated GF Value™ of kr698.10.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for LTS:0QIU:
FCF Margin %: 54.02% (85% above median its 10-year median of 29.13)
GF Value™: kr698.10 vs. price of kr291.00 (58.3% below fair value)
Industry Position: 2052.2% above the Drug Manufacturers median (#190 of 962)
No single metric tells the full story. See the LTS:0QIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score
Get the complete analysis for LTS:0QIU
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QIU has been successfully added to your 
